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Abstract
Walnuts are rich in polyunsaturated fatty acids and have been shown to improve various cardiometabolic risk factors. We
aimed to investigate the association between walnut intake and incident type 2 diabetes in 2 large cohort studies: the
Nurses’ Health Study (NHS) and NHS II. We prospectively followed 58,063 women aged 52–77 y in NHS (1998–2008) and
79,893 women aged 35–52 y in NHS II (1999–2009) without diabetes, cardiovascular disease, or cancer at baseline.
Consumption of walnuts and other nuts was assessed every 4 y using validated food frequency questionnaires. Self-
reported type 2 diabetes was confirmed by a validated supplemental questionnaire. We documented a total of 5930
incident type 2 diabetes cases during 10 y of follow-up. In the multivariable-adjusted Cox proportional hazards model
without body mass index (BMI), walnut consumption was associated with a lower risk of type 2 diabetes, and the HRs
(95% CIs) for participants consuming 1–3 servings/mo (1 serving = 28 g), 1 serving/wk, and $2 servings/wk of walnuts
were 0.93 (0.88–0.99), 0.81 (0.70–0.94), and 0.67 (0.54–0.82) compared with womenwho never/rarely consumedwalnuts
(P-trend < 0.001). Further adjustment for updated BMI slightly attenuated the association and the HRs (95% CIs) were
0.96 (0.90–1.02), 0.87 (0.75–1.01), and 0.76 (0.62–0.94), respectively (P-trend = 0.002). The consumption of total nuts
(P-trend < 0.001) and other tree nuts (P-trend = 0.03) was also inversely associated with risk of type 2 diabetes, and the
associations were largely explained by BMI. Our results suggest that higher walnut consumption is associated with a
significantly lower risk of type 2 diabetes in women. J. Nutr. 143: 512–518, 2013.
Introduction
Diabetes is estimated to affect 25.6 million American adults (1)
and 366 million people worldwide (2), and the numbers will
continue to increase to ~552 million by 2030 globally (2). Type 2
diabetes makes up >90% of all diabetes cases. Therefore, pri-
mary prevention of type 2 diabetes through diet and lifestyle
modifications is of paramount public health importance. Recent
evidence suggests that the type of fat rather than total fat intake
plays an important role in the development of type 2 diabetes
(3,4). Studies have shown that a higher intake of MUFAs and
PUFAs and a lower intake of saturated fat and trans fat is
associated with a reduced risk of type 2 diabetes (4).
The relationship between regular nut consumption and type
2 diabetes risk has attracted a great deal of attention. Although
nuts are high in fats, most of the fats are MUFAs and PUFAs (5).
Nuts also contain other bioactive compounds that appear to
exert favorable effects on type 2 diabetes, including vegetable
proteins, plant sterols, dietary fiber, and antioxidants (5). A
previous analysis from the Nurses’ Health Study (NHS) reported
an inverse relation between frequent nut consumption and risk
of incident type 2 diabetes (6); however, the association with
specific types of tree nuts has not been reported.
Despite many commonalities in nutrient contents, substantial
variations in fatty acids content exist among nuts. For example,
compared with other tree nuts, walnuts are uniquely high in
PUFAs (47% in weight) (5), which comprise both n6 PUFAs
(38%) and n3 PUFAs (a-linolenic acid, 18:3n3, 9%). Because of
potential benefits of PUFAs in preventing diabetes, we specifi-
cally investigated the association between walnut consumption
and risk of type 2 diabetes by using data from 2 prospective
cohort studies, NHS and NHS II, with 10 y of follow-up.
Methods
Study population. Details of the 2 cohorts were previously described
(6,7). The NHS consisted of 121,700 registered female nurses from 11
U.S. states who were enrolled in 1976. The NHS II was established in
1989 and was comprised of 116,671 younger female registered nurses
from 14 states. The cohorts have been updated with biennial validated
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questionnaires to collect information on medical history, lifestyle, and
health factors. The cumulative follow-up of both cohorts exceeds 90% of
potential person-times. Women who answered the 1998 questionnaire in
the NHS (n = 84,733, age range 52–77 y) and 1999 questionnaire in the
NHS II (n = 87,499, age range 35–52 y) served as the baseline population
for our current analyses, because the information on walnut consump-
tion was first available in these years. Participants were excluded if they
had diabetes, heart diseases, stroke, or cancer at baseline (n = 25,052 in
the NHS and n = 6681 in the NHS II), implausible energy intake (<500 or
>3500 kcal/d; n = 1179 in the NHS and n = 420 in the NHS II), missing
information on nut variables (n = 373 in the NHS and n = 415 in the
NHS II), or missing information on body weight (n = 66 in the NHS and
n = 90 in the NHS II). These exclusions left a total of 58,063 women in
the NHS and 79,893 women in the NHS II for this analysis. This study
was approved by the institutional review boards of Brigham and
Womens Hospital and Harvard School of Public Health.
Assessment of consumption of walnuts and other nuts. Dietary
information was collected using validated FFQs with over 130 items that
were administered to the participants every 4 y. All FFQs inquired about
how often, on average, participants consumed each food using standard
portion sizes over the past year. There were 9 possible responses, ranging
from ‘‘never or less than once per month’’ to ‘‘six or more times per day.’’
Starting from 1986 in the NHS and 1991 in the NHS II, participants
were asked about their usual intakes of peanuts and tree nuts using
standard portion sizes (small packet or 1 oz, 28 g). The food item of
walnuts was first introduced on the questionnaires in 1998 in the NHS
and 1999 in the NHS II, along with peanuts and other tree nuts.
Although peanuts are botanically classified as legumes, the fatty acid and
nutrient contents of peanuts are similar to other tree nuts; therefore, we
also included peanuts in the current analysis. The total nut consumption
was the sum of walnuts (if available), peanuts, and other tree nuts. A
validation study indicated a correlation coefficient of 0.75 between the
FFQ and four 1-wk diet records for total nuts in the NHS (8).
Ascertainment of incident type 2 diabetes. In both cohorts, a
supplemental questionnaire regarding symptoms, diagnostic tests, and
hypoglycemic therapy was mailed to participants who reported a
diagnosis of diabetes on the main questionnaire. A case of type 2 diabetes
was considered confirmed if at least one of the following was reported on
the supplemental questionnaire according to the 1997 American
Diabetes Association criteria (9): 1) one or more classic symptoms
(excessive thirst, polyuria, weight loss, hunger) plus fasting plasma
glucose concentrations of at least 7.0 mmol/L or random plasma glucose
concentrations of at least 11.1 mmol/L; 2) at least 2 elevated plasma
glucose concentrations on different occasions (fasting concentrations of
at least 7.0 mmol/L, random plasma glucose concentrations of at least
11.1 mmol/L, and/or concentrations of at least 11.1 mmol/L after $2 h
shown by oral glucose tolerance testing) in the absence of symptoms; or
3) treatment with hypoglycemic medication (insulin or oral hypoglyce-
mic agent).
A previous validation study in the NHS suggested that the self-
reported type 2 diabetes diagnosis through supplemental questionnaire
confirmation was highly accurate: of 62 type 2 diabetes cases who were
confirmed by the questionnaire, 61 (98%) were reconfirmed by medical
records (10). Moreover, in another substudy to assess the prevalence of
undiagnosed diabetes in the NHS, only 1 (0.5%) of 200 women who did
not report a previous diagnosis of diabetes had an elevated fasting
plasma glucose or plasma fructosamine concentration in the diabetic
range (11). Only type 2 diabetes cases confirmed by the supplemental
questionnaires were included in the analysis.
Assessment of covariates. In the biennial follow-up questionnaires,
we inquired and updated information on risk factors for chronic
diseases, such as body weight, cigarette smoking, physical activity,
menopausal status, and hormone use. Other dietary variables included in
the statistical models were alcohol intake, whole grains, fruit, vegetables,
fish, red meat, coffee and sugar-sweetened beverages, which have been
updated every 4 y and related to diabetes risk in our previous in-
vestigations. Information about family history of diabetes and race was
also collected.
Statistical analysis. Person-years for each participant were calculated
from the return date of the baseline questionnaire to the date of diagnosis
of type 2 diabetes, death, or the end of the follow-up period (June 30,
2008 for NHS and June 30, 2009 for NHS II), whichever came first.
Given that the 2 cohorts were similar in study design and follow-up
years, they were combined into one database for the current analysis.
Time-dependent Cox proportional hazards models were used to estimate
the HRs of developing type 2 diabetes according to walnut consumption
categories (never/rarely, <1 serving/wk, 1 serving/wk, $2 servings/wk).
In the multivariable analysis, we simultaneously controlled for various
potential confounding factors, including age (continuous), questionnaire-
cycle (each 2-y interval), race (white, non-white), family history of diabetes
(yes, no), smoking status [never, past, current (1–14, 15–24, $25
cigarettes/d)], alcohol intake (0, 0.1–4.9, 5.0–14.9, $15.0 g/d), physical
activity (<3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9, $27.0 metabolic equiva-
lent task-h/wk), postmenopausal status, and menopausal hormone use
[premenopausal, postmenopausal (never, past, or current hormone use)],
use of multivitamin (yes, no), total energy, and other dietary variables
(whole grains, fruits, vegetables, fish, red meat, coffee, and sugar-
sweetened beverages, all in quintiles). In additional analyses, we further
adjusted for BMI (<23.0, 23.0–24.9, 25.0–29.9, 30.0–34.9, $35.0 kg/m2)
to examine the degree to which the association between walnut con-
sumption and type 2 diabetes was mediated by BMI (7). The above
covariates were updated every 2 or 4 y using the most recent data for
each 2-y follow-up interval.
To better represent long-term diet and minimize within-person
variation, we created cumulative averages of food intakes from baseline
to the censoring events (12). We stopped updating the dietary variables
when the participants reported a diagnosis of stroke, myocardial
infarction, angina, or cancer, because these conditions might lead to
changes in dietary intakes (12).Missing values during the follow-upwere
replaced by the carry-forward method.
We also conducted a further analysis to evaluate the association
between total nut and peanut intake and risk of type 2 diabetes in the
2 cohorts. In this particular analysis, we used the 1986 and 1991
questionnaire years as baseline for the NHS and NHS II, respectively. A
total of 59,259 women in the NHS and 91,799 women in the NHS II
were included. The analysis strategy was the same as in the walnut
analysis; however, the 2 cohorts were analyzed separately, because the
follow-up years were different. The results across the 2 cohorts were then
pooled by an inverse variance-weighted, fixed-effect meta-analysis.
Tests for linear trend were conducted by treating the median value for
each category as a continuous variable. All P values were 2-sided and
data were analyzed with SAS 9.2 (SAS Institute).
Results
The baseline characteristics according to the frequency of
walnut consumption in the 2 cohorts are shown in Table 1.
Women with more frequent walnut consumption were older and
tended to weigh less, exercise more, and smoke less than women
with infrequent consumption. Women who ate more walnuts
also consumed more fish, whole grains, fruit and vegetables, and
total energy. Consumption of walnuts was positively correlated
with intakes of peanuts (Spearman correlation coefficient = 0.30)
and other tree nuts (Spearman correlation coefficient = 0.40).
We documented a total of 5930 incident type 2 diabetes cases
(3166 in the NHS and 2764 cases in the NHS II) during 10 y
of follow-up. As shown in Table 2, walnut consumption was
inversely associated with risk of type 2 diabetes. In the
multivariable-adjusted model without BMI, the pooled HRs
(95% CIs) for participants consuming 1–3 servings/mo,
1 serving/wk, and $2 servings/wk of walnuts were 0.93
(0.88–0.99), 0.81 (0.70–0.94), and 0.67 (0.54–0.82), respec-
tively, compared with women who never/rarely consumed
walnuts (P-trend < 0.001). Further adjustment for updated
BMI slightly attenuated the association, and the HRs (95% CIs)
were 0.96 (0.90–1.02), 0.87 (0.75–1.01), and 0.76 (0.62–0.94),
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respectively (P-trend = 0.002). Each 2-servings/wk increment of
walnut intake was associated with 21% (13–29%) and 15% (6–
23%) lower risk of incident type 2 diabetes before and after
adjustment for BMI, respectively. The associations were similar
to adjustments for saturated fat, trans fat, glycemic load, and
cereal fiber instead of adjustment for food variables, and further
adjustment for PUFAs, a-linolenic acid, total fiber, magnesium,
and arginine did not change the results (data not shown). We
did not find any interaction between walnut consumption and
obesity status, physical activity, dietary quality, and family
history of diabetes in the risk of type 2 diabetes (data not
shown). For other tree nuts, we also found an inverse association
with risk of type 2 diabetes. In the multivariable-adjusted model
without BMI, the pooled HRs (95% CIs) for participants
consuming 1–3 servings/mo, 1 serving/wk, and $2 servings/wk
of other tree nuts were 0.99 (0.94–1.06), 0.93 (0.83–1.04),
and 0.88 (0.77–0.99) compared with women who never/rarely
consumed other tree nuts (P-trend = 0.03). However, the asso-
ciation was attenuated to null after further adjustment for BMI.
We further examined the relation of total nut (including
peanut, walnut, and other nuts) and peanut intakes with risk of
type 2 diabetes (Table 3). Total nut consumption was associated
with a lower risk of incident type 2 diabetes before adjustment
for BMI in both cohorts. In the pooled analysis, the HRs (95%
CIs) for participants consuming 1–3 servings/mo, 1 serving/wk,
2–4 servings/wk, and $5 servings/wk of total nuts were 0.96
(0.92–1.01), 0.95 (0.89–1.02), 0.89 (0.80–0.98), and 0.84
(0.75–0.93), respectively, compared with women who never/
rarely consumed nuts (P-trend < 0.001). However, the associ-
ation was attenuated to null after adjustment for BMI (P-trend =
0.95). Frequent consumption of total tree nuts was also asso-
ciated with a trend toward a lower risk of incident type 2 diabetes
before adjustment for BMI (HR = 0.85; 95% CI: 0.75–0.95;
comparing $2 servings/wk vs. never/rarely; P-trend = 0.054),
TABLE 1 Baseline characteristics according to walnut consumption categories in the 2 prospective
cohorts1
Characteristic Total sample
Frequency of walnut consumption
Never/rarely ,1 serving/wk 1 serving/wk $2 servings/wk P-trend
n 137,956 107,333 24,022 4716 1885 —
Age, y 52.2 6 11.1 51.9 6 11.2 52.8 6 10.6 53.6 6 10.7 55.0 6 11.2 ,0.001
BMI, kg/m2 26.3 6 5.6 26.3 6 5.6 26.2 6 5.5 26.0 6 5.5 25.4 6 5.2 ,0.001
Physical activity, metabolic equivalent
task-h/wk
18.5 6 22.8 18.0 6 22.5 19.9 6 23.0 22.2 6 25.9 23.7 6 28.1 ,0.001
Family history of diabetes, n (%) 43,178 (31.3) 33,565 (31.3) 7546 (31.4) 1471 (31.2) 596 (31.6) 0.73
Menopausal status, n (%) ,0.001
Premenopausal 66,226 (48.0) 52,865 (49.3) 10,645 (44.3) 1998 (42.4) 718 (38.1)
Postmenopausal, no hormone use 14,295 (10.4) 11,043 (10.3) 2510 (10.5) 514 (10.9) 228 (12.1)
Postmenopausal, past hormone use 19,162 (13.9) 14,658 (13.7) 3468 (14.4) 703 (14.9) 333 (17.7
Postmenopausal, current hormone use 29,442 (21.3) 21,798 (20.3) 5954 (24.8) 1204 (25.5) 486 (25.8)
Missing value 8831 (6.4) 6969 (6.5) 1445 (6.0) 297 (6.3) 120 (6.4)
History of hypertension, n (%) 33,470 (24.3) 26,189 (24.4) 5729 (23.9) 1104 (23.4) 448 (23.8) ,0.001
History of hypercholesterolemia, n (%) 52,174 (37.8) 40,347 (37.6) 9197 (38.3) 1843 (39.1) 787 (41.8) 48.1
Current smoker, n (%) 13,332 (9.7) 10,910 (10.2) 2005 (8.4) 317 (6.7) 100 (5.3) ,0.001
White, n (%) 133,828 (97.0) 104,104 (97.0) 23,339 (97.2) 4577 (97.1) 1808 (95.9) 0.56
Multivitamin use, n (%) 67,124 (48.7) 51,650 (48.1) 11,890 (49.5) 2532 (53.7) 1052 (55.8) ,0.001
Alcohol consumption, g/d 4.5 6 8.2 4.5 6 8.2 4.8 6 8.0 4.9 6 7.6 4.6 6 8.2 0.10
Total energy intake, kcal/d 1790 6 558 1730 6 540 1980 6 555 2100 6 585 2160 6 577 ,0.001
Whole grain intake, g/d 27.5 6 18.2 27.3 6 18.4 27.7 6 17.0 28.7 6 17.2 30.1 6 19.6 ,0.001
Red/processed meat intake, g/d 60.6 6 45.4 59.7 6 44.6 64.6 6 46.1 64.1 6 55.1 56.2 6 54.9 0.01
Fish intake, g/d 18.9 6 19.0 17.8 6 18.3 22.1 6 19.7 25.2 6 23.3 25.4 6 26.9 ,0.001
Poultry intake, g/d 58.5 6 45.1 57.8 6 44.8 60.3 6 43.7 63.1 6 55.5 59.1 6 52.5 ,0.001
Vegetable intake, g/d 245 6 153 232 6 145 281 6 160 312 6 192 341 6 216 ,0.001
Fruit intake, g/d 161 6 124 152 6 121 184 6 125 209 6 137 229 6 166 ,0.001
Coffee, g/d 389 6 372 389 6 372 398 6 375 393 6 375 375 6 382 0.79
Sugar-sweetened beverage, g/d 158 6 302 162 6 310 151 6 281 137 6 263 122 6 266 ,0.001
Fiber, g/d 19.7 6 6.0 19.4 6 5.9 20.3 6 5.8 21.6 6 6.5 22.9 6 7.2 ,0.001
Glycemic load 122 6 24 123 6 24 118 6 22 115 6 23 107 6 28 ,0.001
Total fats, g/d 57.3 6 14.2 56.6 6 14.2 59.1 6 13.4 60.7 6 15.1 66.4 6 18.6 ,0.001
PUFA to SFA ratio 0.58 6 0.20 0.58 6 0.20 0.65 6 0.21 0.72 6 0.24 1.07 6 0.46 ,0.001
a-Linolenic acid, g/d 1.00 6 0.36 0.93 6 0.31 1.13 6 0.29 1.24 6 0.30 2.08 6 0.73 ,0.001
Magnesium, mg/d 348 6 97 345 6 98 355 6 92 369 6 96 399 6 106 ,0.001
Arginine, g/d 4.04 6 0.85 4.03 6 0.86 4.06 6 0.79 4.14 6 0.88 4.33 6 1.04 ,0.001
Walnut intake, g/d 0.56 6 2.24 0 6 0 1.96 6 0 3.92 6 0 16.2 6 1.96 ,0.001
Peanut intake, g/d 1.40 6 3.92 1.12 6 3.36 2.24 6 0.15 3.92 6 5.60 5.88 6 9.24 ,0.001
Other nut intake, g/d 1.12 6 3.64 0.84 6 3.36 1.96 6 3.92 3.64 6 5.60 7.84 6 9.52 ,0.001
Total nut intake, g/d 3.36 6 3.92 1.96 6 5.04 5.88 6 6.16 3.92 6 8.12 28.0 6 13.4 ,0.001
1 Data are mean 6 SD or n (%) as specified. 1 serving of walnuts = 28 g.
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but not after adjustment for BMI. There was also an inverse
trend for peanut consumption before adjustment for BMI, but
the association became nonsignificant after further adjustment
for BMI.
Discussion
In 2 large prospective cohorts of U.S. women, we found an
inverse association between walnut consumption and risk of
type 2 diabetes. This association was attenuated but remained
significant after adjusting for BMI. Consistent with our previous
analyses, regular consumption of peanut and tree nuts was also
associated with a significantly lower risk of type 2 diabetes, but
these associations were largely explained by body weight.
Compared with other nuts, which typically contain a high
amount of monounsaturated fats, walnuts are unique because
they are rich in PUFAs (47% in weight), with 38% as linoleic
acid and 9% as a-linolenic acid (5). Because of their fatty acid
composition, walnuts increase circulating concentrations of
PUFAs, particularly linoleic acid and a-linolenic acid (13–16),
which may favorably influence insulin resistance (17) and risk of
type 2 diabetes (4). Walnuts also have high amounts of dietary
fiber, antioxidants, and phytosterol (18,19). Growing evidence
from dietary intervention studies suggests beneficial effects of
walnut consumption on lipid profile (20). In the meta-analysis
by Banel et al. (20), walnut-rich dietary interventions signif-
icantly decreased total cholesterol by 0.27 mmol/L and LDL
cholesterol by 0.24 mmol/L, without affecting HDL cholesterol
and TGs. Despite concerns that high amounts of unsaturated
fatty acids may promote oxidative stress, several intervention
studies found that oxidative stress markers remained unchanged
during walnut interventions despite increased intakes of PUFAs
(21–23). In several feeding studies, markers of endothelial
function, including vascular cell adhesion molecule 1, were
significantly reduced by walnut diets compared with control
diets. In other clinical trials, walnut diets improved markers of
endothelial function (24–27), ameliorated central obesity and
improved metabolic syndrome parameters (16), and increased
circulating total adiponectin and apoA concentrations (28).
In the present study, we found that total nut consumption
was associated with a lower risk of incident type 2 diabetes;
however, the association was attenuated and became nonsignif-
icant after controlling for BMI. Women with frequent nut con-
sumption tended to be leaner than those who rarely consumed
nuts at baseline (6), and previous studies in our cohorts revealed
that frequent nut consumption was associated with less weight
gain (7). Therefore, it is possible that body weight mediated the
association between nut consumption and reduced risk of type 2
diabetes. Despite their high energy and high fat content, nut
consumption does not appear to induce weight gain in many
intervention studies (29) and may increase satiation (30). Cross-
sectional and prospective cohort studies showed that nut con-
sumption was related to a low risk of metabolic syndrome
(31,32). Several short-term intervention studies suggested ben-
eficial effects of nut consumption on lipid profile (33,34),
inflammatory markers and endothelial function (35), oxidative
stress (36,37), insulin secretion (38), and glucose homeostasis
(39), which may explain the inverse association between ha-
bitual nut consumption and risk of type 2 diabetes. It is worth
noting that a higher consumption of different types of nuts,
including almonds, walnuts, and peanuts, appears to have simi-
lar benefits on blood lipids (40). Although the inverse associa-
tion observed for walnuts appeared to be stronger than for total
nuts or other tree nuts, a formal comparison of the benefits of
different types of tree nuts was not possible, because we did not
specifically assess consumption of other tree nuts.
Recently, results from the PREDIMED randomized trial
suggested that a Mediterranean diet supplemented with 30 g/d
nuts (50% walnuts, 25% almonds, and 25% hazelnuts) signif-
icantly reduced risk of metabolic syndrome (41) and incidence of
type 2 diabetes (42) compared with the low-fat control diet.
Intervention studies found that 56 g/d of mixed nuts as a re-
placement for carbohydrate foods improved glycemic control in
patients with type 2 diabetes (43). Several other clinical trials
specifically used walnuts as the intervention food and found
benefits on blood lipids (44) and endothelial function (27). This
evidence supports a role of nut consumption in the prevention
and management of diabetes.
TABLE 2 Relationships between walnut consumption and risk of type 2 diabetes in the 2 prospective
cohorts of women1
Frequency of walnut consumption
P-trend
HR (95% CI)
for 2 servings/wkNever/rarely ,1 serving/wk 1 serving/wk $2 servings/wk
Walnuts
Cases/person-years 4224/91,6280 1433/320,434 183/49,687 90/29,180 5930/131,5581
Age-adjusted model 1.00 0.90 (0.84–0.95) 0.75 (0.64–0.87) 0.61 (0.49–0.75) ,0.001 0.73 (0.66–0.81)
Multivariable model2 1.00 0.93 (0.88–0.99) 0.81 (0.70–0.94) 0.67 (0.54–0.82) ,0.001 0.79 (0.71–0.87)
Multivariable model + BMI3 1.00 0.96 (0.90–1.02) 0.87 (0.75–1.01) 0.76 (0.62–0.94) 0.002 0.85 (0.77–0.94)
Other tree nuts
Cases/person-years 3672/79,5074 1624/355,405 349/88,720 285/76,381 5930/131,5581
Age-adjusted model 1.00 0.96 (0.91–1.02) 0.84 (0.75–0.94) 0.78 (0.69–0.88) ,0.001 0.90 (0.85–0.95)
Multivariable model2 1.00 0.99 (0.94–1.06) 0.93 (0.83–1.04) 0.88 (0.77–0.99) 0.03 0.94 (0.90–0.99)
Multivariable model + BMI3 1.00 1.01 (0.95–1.08) 1.01 (0.90–1.13) 1.04 (0.92–1.18) 0.49 1.02 (0.97–1.07)
1 Data are based on a pooled database of 10 y of follow-up in the NHS (1998–2008) and NHS II (1999–2009). 1 serving of walnuts = 28 g.
NHS, Nurses Health Study.
2 Multivariable model: adjusted for age (continuous), race (white, non-white), family history of diabetes (yes, no), smoking status [never,
past, current (1–14, 15–24, $25 cigarettes/d)], alcohol intake (0, 0.1–4.9, 5.0–14.9, $15.0 g/d), physical activity (,3.0, 3.0–8.9, 9.0–17.9,
18.0–26.9, $27.0 metabolic equivalent task-h/wk), postmenopausal status and menopausal hormone use [premenopausal, postmeno-
pausal (no, past, or current hormone use)], use of multivitamin (yes, no), total energy intake, and other dietary variables (all in quintiles),
including whole grains, fruits, vegetables, fish, red meat, coffee, and sugar-sweetened beverages.
3 Multivariable model + BMI: ,23.0, 23.0–24.9, 25.0–29.9, 30.0–34.9, $35 kg/m2.
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The strengths of the current study include a large sample size,
a prospective design, and repeated assessments of diet and
lifestyle variables. Our study has several potential limitations.
First, our study populations primarily consisted of white female
nurses, which may limit the generalizability of the findings to
other ethnic groups or males. Second, because diet was assessed
by FFQs, measurement error of nut intake is inevitable, which
may underestimate the true associations. Third, biochemical
markers for type 2 diabetes (fasting glucose, insulin, lipids, and
HbA1C, etc.) were not available in the full NHS cohorts, and
thus could not be adjusted in the models. Furthermore, habitual
nut consumption was associated with several healthy lifestyle
TABLE 3 Cohort-specific and pooled results for the relationships between total nuts and peanut consumption and risk of type 2
diabetes in the 2 prospective cohorts of women1
NHS (1986–2008)
Frequency of nut consumption
P-trend
HR (95% CI)
for 2 servings/wkNever/rarely ,1 serving/wk 1 serving/wk 2–4 servings/wk $5 servings/wk
Total nuts
Cases/person-years 1713/370,858 2117/479,539 694/151,885 318/82,750 279/79,216 5121/116,4248
Age-adjusted model 1.00 0.92 (0.87–0.98) 0.90 (0.82–0.98) 0.80 (0.71–0.90) 0.74 (0.65–0.84) ,0.001 0.90 (0.86–0.94)
Multivariable model2 1.00 0.97 (0.91–1.04) 1.00 (0.91–1.09) 0.91 (0.80–1.02) 0.87 (0.77–0.99) 0.051 0.96 (0.92–1.00)
Multivariable model + BMI3 1.00 0.99 (0.92–1.05) 1.05 (0.96–1.15) 0.98 (0.87–1.11) 1.00 (0.87–1.14) 0.84 1.00 (0.96–1.05)
Total tree nuts
Cases/person-years 3204/691,101 1368/334,154 331/80,486 218/58,506 5121/116,4248
Age-adjusted model 1.00 0.95 (0.89–1.02) 0.91 (0.81–1.02) 0.75 (0.66–0.87) 0.002 0.91 (0.86–0.97)
Multivariable model2 1.00 1.01 (0.95–1.08) 1.01 (0.90–1.14) 0.91 (0.79–1.05) 0.70 0.99 (0.94–1.05)
Multivariable model + BMI3 1.00 1.03 (0.96–1.10) 1.07 (0.95–1.19) 1.00 (0.86–1.15) 0.28 1.03 (0.98–1.09)
Peanuts
Cases/person-years 2415/532,763 1953/438,313 471/115,823 282/77,349 5121/116,4248
Age-adjusted model 1.00 0.99 (0.93–1.05) 0.92 (0.83–1.01) 0.84 (0.75–0.95) 0.009 0.92 (0.87–0.98)
Multivariable model2 1.00 1.01 (0.95–1.07) 0.99 (0.89–1.09) 0.93 (0.82–1.06) 0.41 0.98 (0.92–1.03)
Multivariable model + BMI3 1.00 1.03 (0.97–1.09) 1.06 (0.95–1.17) 1.05 (0.92–1.19) 0.38 1.03 (0.97–1.09)
NHS II (1991–2009)
Total nuts
Cases/person-years 1691/714164 1676/622,298 414/147,139 185/66,544 132/49,522 4098/159,9667
Age-adjusted model 1.00 0.98 (0.91–1.05) 0.88 (0.79–0.98) 0.86 (0.74–1.00) 0.78 (0.65–0.93) ,0.001 0.88 (0.83–0.94)
Multivariable model2 1.00 0.95 (0.88–1.02) 0.89 (0.79–0.99) 0.86 (0.73–1.00) 0.77 (0.64–0.92) ,0.001 0.89 (0.83–0.94)
Multivariable model + BMI3 1.00 0.99 (0.92–1.06) 1.00 (0.89–1.12) 1.00 (0.86–1.17) 1.02 (0.85–1.23) 0.69 0.99 (0.93–1.05)
Total tree nuts
Cases/person-years 2632/1,047,652 1185/438,580 200/77,904 81/35,532 4098/1,599,667
Age-adjusted model 1.00 0.96 (0.90–1.03) 0.82 (0.71–0.95) 0.68 (0.55–0.85) ,0.001 0.80 (0.71–0.89)
Multivariable model2 1.00 0.95 (0.89–1.02) 0.88 (0.76–1.02) 0.70 (0.56–0.91) ,0.001 0.82 (0.74–0.92)
Multivariable model + BMI3 1.00 1.00 (0.93–1.08) 1.03 (0.89–1.19) 0.94 (0.75–1.17) 0.68 0.98 (0.88–1.08)
Peanuts
Cases/person-years 2303/940,712 1466/540,865 241/85,875 88/32,215 4098/1,599,667
Age-adjusted model 1.00 1.02 (0.96–1.09) 1.02 (0.89–1.17) 0.90 (0.73–1.12) 0.14 0.93 (0.83–1.03)
Multivariable model2 1.00 0.97 (0.90–1.03) 0.98 (0.86–1.12) 0.84 (0.68–1.04) 0.02 0.88 (0.79–0.98)
Multivariable model + BMI3 1.00 1.01 (0.94–1.08) 1.11 (0.97–1.27) 1.01 (0.81–1.25) 0.95 1.00 (0.90–1.12)
Pooled results4
Total nuts
Age-adjusted model 1.00 0.95 (0.91–0.99) 0.89 (0.83–0.95) 0.82 (0.75–0.90) 0.75 (0.68–0.84) ,0.001 0.90 (0.87–0.93)
Multivariable model2 1.00 0.96 (0.92–1.01) 0.95 (0.89–1.02) 0.89 (0.80–0.98) 0.84 (0.75–0.93) ,0.001 0.93 (0.90–0.97)
Multivariable model + BMI3 1.00 0.99 (0.94–1.04) 1.03 (0.96–1.10) 0.99 (0.90–1.09) 1.01 (0.90–1.12) 0.95 1.00 (0.97–1.03)
Total tree nuts
Age-adjusted model 1.00 0.96 (0.91–1.00) 0.87 (0.80–0.96) 0.73 (0.65–0.82) ,0.001 0.89 (0.84–0.93)
Multivariable model2 1.00 0.98 (0.94–1.03) 0.96 (0.88–1.05) 0.85 (0.75–0.95) 0.054 0.95 (0.91–1.00)
Multivariable model + BMI3 1.00 1.02 (0.97–1.07) 1.05 (0.96–1.15) 0.98 (0.87–1.10) 0.44 1.02 (0.97–1.07)
Peanuts
Age-adjusted model 1.00 1.00 (0.96–1.05) 0.95 (0.88–1.03) 0.86 (0.77–0.96) 0.003 0.92 (0.88–0.97)
Multivariable model2 1.00 0.99 (0.95–1.04) 0.98 (0.91–1.07) 0.91 (0.81–1.01) 0.07 0.95 (0.90–1.00)
Multivariable model + BMI3 1.00 1.02 (0.97–1.06) 1.07 (0.99–1.17) 1.04 (0.93–1.16) 0.42 1.02 (0.97–1.07)
1 Data are based on 22 y of follow-up in the NHS (1986–2008), and 18 y of follow, up in the NHS II (1991–2009). 1 serving of walnuts = 28 g. NHS, Nurses Health Study.
2 Multivariable model: adjusted for age (continuous), race (white, non-white), family history of diabetes (yes, no), smoking status [never, past, current (1–14, 15–24, $25
cigarettes/d)], alcohol intake (0, 0.1–4.9, 5.0–14.9,$15.0 g/d), physical activity (,3.0, 3.0–8.9, 9.0–17.9, 18.0–26.9,$27.0 metabolic equivalent task-h/wk), postmenopausal status
and menopausal hormone use [premenopausal, postmenopausal (no, past, or current hormone use)], use of multivitamin (yes, no), total energy intake, and other dietary variables
(all in quintiles), including whole grains, fruits, vegetables, fish, red meat, coffee, and sugar-sweetened beverages.
3 Multivariable model + BMI: ,23.0, 23.0–24.9, 25.0–29.9, 30.0–34.9, $35 kg/m2.
4 The results were pooled by a fixed-effect meta-analysis across the 2 cohorts.
516 Pan et al.
practices and may be a marker for an overall healthy lifestyle.
Although we carefully controlled for a number of diabetes risk
factors, unmeasured and residual confounding is still possible
to explain the association and we could not fully exclude the
potential influence from the overall diet quality and healthy
cuisine effects. Finally, although causation cannot be inferred
from our analysis, the consistent evidence from experimental
and epidemiological studies and clinical trials provides support
for the hypothesis that regular consumption of nuts, particularly
walnuts, as a component of a healthy diet profile is associated
with lower incidence of type 2 diabetes.
In conclusion, the present analysis indicates that frequent
intake of walnuts was associated with a lower risk of incident
type 2 diabetes in women, the association persisted after ad-
justment for other lifestyle factors, and it was partially mediated
by BMI. The inverse association between other tree nuts and
total nuts with type 2 diabetes was largely explained by BMI.
Further studies are needed to confirm our results, particularly
the association between walnut consumption and risk of type
2 diabetes. The findings from our study and others support the
benefits of the incorporation of nuts, including walnuts, as a
component of a healthy diet for diabetes prevention.
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